Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend. The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend. Shares of ARQT have been moving higher over the past four weeks, up 12.1%. Plus, the company is currently a Zacks Rank #2 (Buy) stock, suggesting that ARQT could be poised for a continued surge. Once investors consider ARQT's positive earnings estimate revisions, the bullish case only solidifies. No estimate has gone lower in the past two months for the current fiscal year,
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology MeetingGlobeNewswire
- Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
ARQT
Earnings
- 2/25/25 - Beat
ARQT
Sec Filings
- 3/17/25 - Form 4
- 3/14/25 - Form 144
- 3/13/25 - Form 144
- ARQT's page on the SEC website